Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $3.13 | N/A |
Market Cap | $40.69M | N/A |
Shares Outstanding | 13.02M | N/A |
Employees | 8.00 | N/A |